comparemela.com

Latest Breaking News On - Anti cancer activity - Page 2 : comparemela.com

Study Reveals Anti-cancer Activity of Capsaicin Formulations

Researchers provide the first published in-depth description of the anti-cancer activity of capsaicin sustained-release formulations.

Capsaicin formulationsAnti cancer activityChili peppersSustained releaseSpicy flavor

The Buzz Show: Onconova Therapeutics Inc (NASDAQ: ONTX) Anti-Cancer Clinical Data

The Buzz Show: Onconova Therapeutics Inc (NASDAQ: ONTX) Anti-Cancer Clinical Data
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

Onconova therapeutics incBuzz showFeaturing our corporate news recapAnti cancer activityTherapeutics incOnconova therapeutics

NuCana plc: NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

NuCana plc: NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors NUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3 -dATP Acelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021. Data from all three of NuCana s ProTides in clinical development were presented. Summaries of the posters are described below.

United statesUnited kingdomCity ofHughs griffithMarion janicNucana protidesChris brinzeyCompany annual report on formExchange commissionAmerican association for cancer researchEncouraging efficacy signalsFavorable safety profileAdvanced colorectalNatural killer cell activationColorectal cancerAnti cancer activity

Investegate |NuCana plc Announcements | NuCana plc: NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

NuCana plc NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors NUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3’-dATP Acelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually

United statesUnited kingdomCity ofHughs griffithMarion janicNucana protidesChris brinzeyCompany annual report on formExchange commissionAmerican association for cancer researchNucana announces five poster presentationsAmerican associationCancer researchAnnual meetingEncouraging efficacy signalsFavorable safety profile

VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer

Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer Tumors Veru Plans to Meet with FDA and Advance VERU-111 into a Phase 2b Clinical Trial in Women with Paclitaxel Resistant Triple Negative Breast Cancer in 2021 MIAMI, Dec. 14, 2020 (GLOBE NEWSWIRE) Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announces the presentation of preclinical data demonstrating the efficacy of oral VERU-111 in the treatment of human derived animal models of triple negative breast cancer at the 2020 San Antonio Breast Cancer Symposium.

United statesSan antonioSam fischCompany sexual health businessCompany formExchange commissionProfessor of pharmaceutical sciencesCompany female health divisionVeru incUniversity of tennessee health science centerData presentedAntonio breast cancerAnti cancer activityBoth paclitaxel sensitiveVeru plansClinical trial

vimarsana © 2020. All Rights Reserved.